abrdn plc acquired a new stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 138,791 shares of the biotechnology company's stock, valued at approximately $17,481,000. abrdn plc owned 0.24% of Ascendis Pharma A/S at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in the stock. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 31.9% in the 3rd quarter. Signaturefd LLC now owns 798 shares of the biotechnology company's stock worth $75,000 after buying an additional 193 shares during the period. China Universal Asset Management Co. Ltd. grew its position in shares of Ascendis Pharma A/S by 95.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,462 shares of the biotechnology company's stock worth $137,000 after buying an additional 714 shares during the period. Legato Capital Management LLC purchased a new stake in shares of Ascendis Pharma A/S in the 4th quarter worth about $204,000. Gilbert & Cook Inc. purchased a new stake in shares of Ascendis Pharma A/S in the 3rd quarter worth about $245,000. Finally, Sectoral Asset Management Inc. grew its position in shares of Ascendis Pharma A/S by 51.7% in the 3rd quarter. Sectoral Asset Management Inc. now owns 4,241 shares of the biotechnology company's stock worth $397,000 after buying an additional 1,445 shares during the period.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on ASND. JPMorgan Chase & Co. upped their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 2nd. Wells Fargo & Company upped their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an "overweight" rating in a research note on Friday, March 15th. Wedbush upped their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an "outperform" rating in a research note on Thursday, February 8th. Citigroup upped their target price on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a "buy" rating in a research note on Thursday, February 8th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $173.00 target price on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.
Check Out Our Latest Stock Report on ASND
Ascendis Pharma A/S Price Performance
Shares of NASDAQ:ASND traded down $6.25 during trading on Thursday, hitting $136.93. The company's stock had a trading volume of 376,771 shares, compared to its average volume of 368,318. The company has a 50-day moving average of $149.08 and a 200-day moving average of $125.60. Ascendis Pharma A/S has a 12 month low of $66.03 and a 12 month high of $161.00. The firm has a market cap of $7.97 billion, a price-to-earnings ratio of -14.80 and a beta of 0.50.
Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $0.49. The firm had revenue of $148.62 million for the quarter, compared to analysts' expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. As a group, research analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.
Ascendis Pharma A/S Company Profile
(
Free Report)
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.
Further Reading
Before you consider Ascendis Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascendis Pharma A/S wasn't on the list.
While Ascendis Pharma A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
